( of Aquavan 6.5 mg/kg achieved sedation...)Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007,Health

of Aquavan 6.5 mg/kg achieved sedation success, which was defined by three consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of greater than or equal to 4, plus completion of the procedure without the need for alternative sedative medications and manual or mechanical airway assistance. In comparison, 26% of patients who received Aquavan 2.0 mg/kg achieved sedation success (pless than0.001), while 69% who received midazolam 0.02 mg/kg achieved sedation success. MOAA/S scores measure a patient's sedation level.

Furthermore, 88% of patients in the Aquavan 6.5 mg/kg treatment arm achieved "treatment success," the secondary efficacy endpoint of the trial, meaning they completed their colonoscopy without requiring manual/mechanical ventilation and alternative sedative medication (non-study sedative(s) used because of inadequate sedation). By comparison, 28% of patients in the Aquavan 2.0 mg/kg treatment arm achieved treatment success (pless than0.001). In addition, the 6.5 mg/kg dose of Aquavan was associated with a lower rate of supplemental analgesic use (55% of patients required additional analgesic medication, compared to 77% receiving the 2.0 mg/kg dose, pless than0.001). The most common adverse reactions were paresthesias (abnormal neurological sensations, such as increased sensitivity, numbness, tingling, and burning) and pruritis (itching). These were generally mild in intensity, transient and self-limiting. Results from this pivotal phase 3 trial have been reported previously.

Physician/Patient Satisfaction (Abstract W1440) and Procedural Recovery (Abstract W1441) Analyzed

Additional endpoints of the phase 3 study were analyzed prospectively in two sub-analyses to assess physician- and patient-reported satisfaction as well as patients' cognition during recovery. In the first sub-analysis, physicians used a 10-point scale (1 = low, 10 = high) to rate their experience with both Aquavan doses at the end of the sed
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
7. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
8. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
9. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
10. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting